Tecentriq improves PFS by 1.7 months in first-line TNBC

Genentech Inc. reported in October additional data from the Phase III IMpassion130 trial to treat triple-negative breast cancer (TNBC) showing that Tecentriq atezolizumab plus Abraxane nab-paclitaxel as first-line treatment increased median progression-free survival (PFS) vs. placebo plus Abraxane by 1.7 months in the intent-to-treat (ITT) population (7.2 vs. 5.5 months, HR=0.8, 95% CI: 0.69, 0.92, p=0.0025) and by 2.5 months in the PD-L1-positive population (7.5 vs. 5 months, HR=0.62, 95% CI: 0.49, 0.78, p<0.0001). Data were presented at the European Society for Medical Oncology meeting in Munich and published in the New England Journal of Medicine.

The Roche (SIX:ROG; OTCQX:RHHBY) unit reported in July that the Tecentriq arm met the co-primary endpoint of improving PFS in both populations (see "Tecentriq Meets PFS Endpoint in First-Line TNBC")...